This week's innovators to know in Houston includes Ayse McCracken of Ignite Healthcare Network, Philipp Sitter of VIPinsiders, and Diane Yoo of Medingenii. Photos courtesy

Editor's note: In today's Monday roundup of Houston innovators, I'm introducing you to three innovators — from health care investing to marketing technology — all making headlines in Houston this week.

Ayse McCracken, founder and board chair of Ignite Healthcare Network

Ayse McCracken joins the Houston Innovators Podcast to discuss women in health care and Ignite Madness. Photo courtesy of Ignite

When the pandemic hit and shut down businesses across the world, Ayse McCracken knew immediately what group of people were likely going to be the most affected: Women in health care. It just so happens that her nonprofit organization, Ignite Healthcare Network, exists to serve this same group of people, so she got to work on creating online events that were intentional and meaningful.

"With COVID, it has only escalated the importance of our work, so we've elevated our voices through our webinar series," McCracken says on this week's Houston Innovators Podcast.

This week, Ignite's virtual startup competition concludes with the finals. She shares more about the program and Ignite's mission on the episode. Click here to read more and stream the episode.

Philipp Sitter, founder of VIPinsiders

Restaurateur Philipp Sitter launched VIPinsiders last year. Photo courtesy of VIPinsiders

Restaurants have undoubtedly suffered due to loss of business during the shutdown, but they face an uphill battle back to normalcy, and restaurateur Philipp Sitter knew his tech tool could help. He created VIPinsiders as a marketing tool to reach customers in a data-driven way.

"The restaurant gets to know me [the customer], it understands how often I visit, it also gets to reward my visitation," explains Sitter. "Most importantly, it reminds me to come back when I haven't visited in a while."

Data recorded by VIPinsiders shows that 48 percent of users visit restaurants with the platform "more often" in the first 90 days. Click here to read more.

Diane Yoo, managing partner at Medingenii

Diane Yoo, who was hospitalized due to COVID-19 earlier this year, created a VC fund that's investing in health tech solutions for the disease. Photo courtesy of Medingenii

Just a few weeks after being hospitalized from COVID-19, Diane Yoo was investing in a medical device startup that could have made a world of difference to her recovery. After closing its initial fund, Medingenii invested in several Houston health startups including Vitls, a wearable device that can track and send vitals remotely.

"The pandemic has really validated some of the business models we're invested in," she tells InnovationMap.

Now, fueled by her first round of success and eager to advance other life-changing technologies, Yoo is looking toward a second fund. Click here to read more.

Diane Yoo, who was hospitalized due to COVID-19 earlier this year, created a VC fund that's investing in health tech solutions for the disease. Photo courtesy of Medingenii

Houston investor recovers from COVID-19 — then funds startups innovating solutions for the disease

money moves

While so many of Houston's venture capital groups and entrepreneurs have been figuring out the best ways to navigate fundraising amid a pandemic, Diane Yoo managed to close an oversubscribed initial fund and deployed investments into health tech startups during COVID-19 — while also recovering from the disease itself.

Entrepreneur turned investor Diane Yoo launched her health tech-focused venture capital fund, Medingenii Capital, last year, but didn't start fundraising for its initial fund until this year.

Yoo says she and her partners, entrepreneur and investor Greg Campbell, neurologist Dr. Eddie Patton, Dr. Sreedhar Mandayam, and investor Gen Fukunaga, were virtually meeting with over a dozen potential investors weekly and closed the round in under two months.

It was right around closing when Yoo says she caught COVID-19.

"It ravaged every part of my body, and I ended up having to be hospitalized because I couldn't breathe," she says.

Yoo recovered after a month and a half of enduring the disease, only to come out of that experience to fund innovative Houston companies working on COVID-19 solutions. Medingenii focuses on early stage health tech, including genomics, health IT, medical devices, and patient engagement.

"The pandemic has really validated some of the business models we're invested in," she tells InnovationMap.

One example from Medingenii's portfolio is Houston-based medical device company, Vitls. The company's technology includes a wearable device that can monitor vital signs and sync with a smartphone app and sends key information to doctors remotely.

As Yoo thinks back to her COVID-19 treatment, Vitls could have helped her and her fellow patients get out of the crowded hospital wing and home to recover sooner — with the peace of mind of remote care thanks to the device.

"When I was in the ER room, it was overcrowded," Yoo says. "If you were not seriously ill, they would dismiss you because there was just no room. But if you went home with Vitls, you could have sent all your vitals to your doctor from home."

Fueled by a mission to find more health tech solutions like Vitls and with the quick pace of her first fund — Yoo says she's already deployed the capital into Houston-based startups and is looking toward the second fund, which will again focus on Houston startups.

"We really love Houston," Yoo says. "We want to invest a lot of our fund here, and we continue to do that and plan to do that. We see a lot of opportunity in Houston and look forward to working with the innovation ecosystem here."

Big companies are using your data to make a profit — but what if you got a kickback of that cash? That's what Houston-based Social Chains is trying to do. Pexels

Houston startup aims to flip the script on social media marketing

anti social media

Social media companies are using user data for their own financial gain, but what if users had a cut in the profits? That's the business model for Houston-based Social Chains.

"Social Chains is a social media platform of real people, real privacy, and real rewards," says Srini Katta, founder and CEO of the company. "We're fixing three problems in the social media industry."

The first problem is that user data has market value, but only the Facebook, Google, and other platforms are reaping the rewards, not the user, who's the backbone of the platform. User privacy and a growing number of fake accounts are the other issues Social Chains addresses. Katta says he realized that most importantly, users should own their data

"On our platform, the user is a stakeholder. Our platform distributes 50 percent of the profits to the users," he says.

User privacy is protected and encrypted on this new platform, and users must register with a government-issued identification. Social Chains prevents fake accounts by using facial recognition.

The biggest differentiating factor of this platform is that users make real money, but it's kept track by the site's token system, which uses blockchain technology, and users receive some of the so-called "S tokens" just for signing up. And, businesses only pay for the ads that users engage with. For instance, for a marketing email, businesses will only pay for the emails that were actually opened. It's a win-win situation, as the user receives a kickback whenever they open a marketing email or engage with ads.

Social Chains already has 5,000 users and, Katta says, that's with little to no marketing efforts. Currently, he's been working out a few kinks before launching into marketing for the platform, though he expects to do that beginning next month. Most of Social Chain's current users are high school to college students, so that will be the primary demographic for the marketing strategy.

Katta says he first encountered some of the challenges using social media marketing at one of his former startups when attempting to use Facebook ads to grow the company. He says he saw increased engagement, but not as significant of an increase in sign ups on his company page.

"We looked back to see who are the people clicking on the ads," he says. "We looked at their profiles, and they were not from the United States, even though we had given geographic preferences."

He found out that third party ad management platforms were working with Facebook and click farms all around the world to increase engagement results. Katta starting thinking of a solution for this marketing problem.

"Then, in 2016, with the rise of 'fake news,' we realized this was a bigger problem," he says.

In addition to user growth, Katta hopes to grow his investors, and the company is seeking funds for its seed round in 2019.

"To be honest, we need $100 million to build this out, so we're trying to raise money," Katta says. "Personally, I've put in $3.5 million before I took any money from investors. I have a lot of skin in the game."

Currently, Social Chains has three team members, with a fourth joining soon. Diane Yoo, who is a founding member and director of the Rice Angel Network, leads growth and investor relations for the company. One obstacle for the team has been being spread out from Houston to The Woodlands and even Austin.

"I've lived in New York and San Francisco. I moved to Houston because I wanted a quiet place to raise my family," Katta says. "The biggest challenge for Houston, compared to other cities, is other cities are so dense. Houston is so sprawling. It's really hard to network, and meet potential employees."

One of the crucial connectors for Katta has been Station Houston. The team plans on meeting to work together two days a week at Station. In addition to being a great workspace, the area acts as a good hub for potential partnerships for Social Chains. Startups need marketing, of course.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Pharma giant considers Houston for $1B manufacturing campus

in the works

Another pharmaceutical giant is considering Houston’s Generation Park for a manufacturing hub.

According to a recent filing with the Texas Jobs, Energy, Technology and Innovation (JETI) program, Bristol Myers Squibb Co. is considering the northeast Houston management district for a new $1 billion multi-modal pharmaceutical manufacturing campus.

If approved, the campus, known as Project Argonaut, could create 489 jobs in Texas by 2031. Jobs would include operations technicians, engineering roles, administrative and management roles, production specialists, maintenance support, and quality control/assurance. The company predicts annual average wages for these positions to be around $96,000, according to the filing.

The project currently includes the 600,000-square-foot facility, but according to the filing, Bristol Myers Squibb “envisions this site growing in scale and capability well beyond its opening configuration."

The Texas JETI program offers companies temporary school property tax limitations in exchange for major capital investment and job creation. E.R. Squibb & Sons LLC applied for a 10-year tax abatement agreement in the Sheldon Independent School District.

The agreement promises a $ 1 billion investment. Construction would begin in 2027 and wrap in 2029.

“The proposed project reflects [Bristol Myers Squibb Co.’s] enduring commitment to bringing innovative medicines to patients and ensuring the long-term supply reliability they depend on,” the filing says. “The proposed project is purpose-built to support and manufacture medicines spanning multiple therapeutic areas and modalities, positioning the site as a long-term launch and commercial campus for decades to come. These medicines will provide therapies to the [Bristol Myers Squibb Co.’s] patients located in markets both nationally and internationally.”

The Fortune 100 company is considering 16 other cities for the new manufacturing facility in the Central and Eastern markets in the U.S. According to the Houston Chronicle, Bristol Myers Squibb Co is still in the “evaluation process” for its potential manufacturing site.

Last fall, Eli Lilly and Co. selected Generation Park for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here.

Houston health tech co. lands NIH grant for AI cancer prediction tool

fresh funding

Houston-based CellChorus and Stanford Medicine were recently awarded a Phase I Small Business Innovation Research grant for the company's AI platform to test how certain cancer patients will respond to therapies.

The funding comes from the National Cancer Institute of the National Institutes of Health. According to a filing, the grant totaled just under $400,000.

CellChorus, which spun out from the University of Houston’s Technology Bridge, has developed TIMING (Time-lapse Imaging Microscopy In Nanowell Grids), which analyzes the behavior of thousands of individual immune cells over time and can identify early indicators of treatment success or failure.

The company will work with Stanford's Dr. David Miklos and Dr. Saurabh Dahiya, who have built the Bone Marrow Transplantation and Cell Therapy Biobank. The biobank manages and stores biological samples from patients treated at their clinic and in clinical trials.

"Predicting which patients will achieve durable responses after CAR-T therapy remains one of the most important challenges in the field,” Miklos said in a news release. “We aim to uncover functional cellular signatures that can guide treatment decisions and improve patient outcomes.”

The project will specifically profile cells from patients with relapsed/refractory large B-cell lymphoma (r/rLBCL). According to CellChorus, only about half of r/rLBCL patients who receive CAR-T therapy "achieve a durable, long-term remission." Others do not respond to therapy or experience relapse.

“The sooner we know whether a cancer therapy is working, the better. To maximize patient benefit, we need technology that can provide a robust and early prediction of response to therapy. The technology needs to be scalable, cost-efficient, and capable of rapid turnaround times,” Rebecca Berdeaux, chief scientific officer of CellChorus, added in the release. “We are excited to work with Drs. David Miklos and Saurabh Dahiya and their colleagues on this very important project.”

CellChorus has previously received SBIR grants from federal agencies, including a $2.5 million award in 2024 from its National Center for Advancing Translational Sciences (NCATS) and a $2.3 million SBIR Fast-Track award from the National Institute of General Medical Sciences in 2023.

Houston museum showcases America's founding documents in rare exhibit

Experience History

As the United States prepares to celebrate its 250th birthday, Houstonians have a chance to see rare documents from the founding of the nation. Freedom Plane National Tour: Documents That Forged a Nation, presented by the National Archives Foundation, will be on display at the Houston Museum of Natural Science through Monday, May 25.

The collection includes a rare engraving of the original Declaration of Independence; official Oaths of Allegiance signed by George Washington, Aaron Burr, and Alexander Hamilton; a draft of the Bill of Rights; the Treaty of Paris, the documented that recognized America's independence from Great Britain; and the tally of votes approving the Constitution.

The National Archives specifically chose Houston as one of only eight cities in the country to host the exhibit as a means to help the documents reach a wider audience outside of the main hub of semiquincentennial events in New England and the Washington, D.C. area.

"One of the things we decided when we put the tour together because we wanted to be off the East Coast," said Patrick Madden, CEO of the National Archives Foundation, who was onsite for the exhibit's opening in Houston. "There's a lot of 250th celebration stuff happening in the original 13 colonies. How do we get it to major markets where larger numbers of people can see it? So in the case of Houston, obviously, [is a] major market in this part of the country, but also we've partnered with the museum twice before with National Archives exhibits, so we knew that they would be up to the task of handling the exhibit and the crowds."

The star of the collection is a rare engraving of the original Declaration of Independence. Secretary of State and future president John Quincy Adams commissioned 200 exact replicas of the document from engraver William J. Stone in 1823. Less than 50 now remain. Madden joyfully pointed out that there are errors in this document, a potent reminder that the men who forged a nation made mistakes.

"There's a couple of typos in it where they had to make corrections," said Madden. "So even the founders, you know, they're all human. That resonates because here these people are making this move against the most powerful nation in the world and putting their lives on the line for a country based on ideas."

Other impressive parts of the collection include official Oaths of Allegiance signed by George Washington, Aaron Burr, and Alexander Hamilton, as well as one of the drafts of the Bill of Rights. Many states would not ratify the Constitution until certain rights were included in the document, leading to Washington going on a national tour assuring state leaders enshrining protections was first on the list. The draft copy on display specifically shows the First Amendment in progress.

Houston is the fourth stop on the exhibition's tour, which will take the documents to Denver, Miami, Dearborn, and Seattle through the summer. Freedom Plane is just one part of a larger patriotic celebration at the HMNS, which includes a film series celebrating American science and culture and general Americana decoration throughout the main hall.

Admission to Freedom Plane is free to the public, but separate from general admission to the museum. Space is limited, and passes are available on a first-come, first-serve basis. Non-members should expect long waits or the possibility that the day's passes are sold out. Only museum members can reserve passes for specific times. Flash photography is prohibited due to the fragile nature of the documents.

---

This article originally appeared on CultureMap.com.